STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Location in study
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	See title on page 1, line 2 "cross-sectional study"
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	See "Abstract" on page 2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	This is covered in page 3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	The objective of this study is on page 4 lines 4-7 and there was no prespecified hypothesis
Methods			
Study design	4	Present key elements of study design early in the paper	An overview of the study design was shared in the first paragraph of the "Methods" section on page 4 lines 14-23
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	See page 4 lines 14-20
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	See page 4 lines 14-20
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	N/a this is a cross-sectional study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	See page 5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	See page 5
Bias	9	Describe any efforts to address potential sources of bias	See page 6 lines 14-16, bootstrapped weighting

Study size	10	Explain how the study size was arrived at	N/a, the sample size was pre-determined by Statistics Canada as a representative sample of all Canadians
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	See page 5-6
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	See "Statistical analysis" section on page 5-6
		(*b*) Describe any methods used to examine subgroups and interactions	N/a, no subgroup analysis or interactions are reported.
		(*c*) Explain how missing data were addressed	See page 5 line 10-11 and page 6 lines 17-18
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	See page 6 lines 14-16, bootstrapped weighting
		(*e*) Describe any sensitivity analyses	N/a, no sensitivity analysis is reported.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/a, the study population included in the final analysis is reported on page 7 line 12
		(b) Give reasons for non-participation at each stage	N/a
		(c) Consider use of a flow diagram	N/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	See page 7 lines 15-18 and Table 1 on page 18
		(b) Indicate number of participants with missing data for each variable of interest	N/a
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	N/a, this is a cross-sectional study
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	N/a, this is a cross-sectional study
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/a, this is a cross-sectional study
		Cross-sectional study—Report numbers of outcome events or summary measures	This is reported on page 7 lines 18-19 and in Figures 1 on page 17

Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Full unadjusted and adjusted estimates with 95%CIs are provided in Table 2 on page 19
		(*b*) Report category boundaries when continuous variables were categorized	N/a, no continuous variables were used
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Absolute measures were calculated and reported as adjusted risk increases and reported on Table 2 on page 19
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/a, no additional analyses are reported
Discussion			
Key results	18	Summarise key results with reference to study objectives	See page 8 lines 10-20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	See page 10 lines 7-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	See "Interpretation" section on page 8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	See page 10 lines 10-11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	See page 1 line 18

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.